Skip to content

The Effect of Inhaled Nitroglycerin for COPD Patients

The Effect of Inhaled Nitroglycerin on Improving Respiratory Failure in COPD Patients Admitted to Adult Intensive Care Unit

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06785337
Acronym
iNGCOPD
Enrollment
40
Registered
2025-01-21
Start date
2025-02-01
Completion date
2025-12-01
Last updated
2025-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD, COPD III/IV

Keywords

Inhaled, nitroglycerin

Brief summary

this study aims to investigative the benefits of using nebulized nitroglycerin in improving respiratory functions in patients of late stage COPD

Detailed description

the inhaled nitroglycerin is expected to make vasodilatation of the pulmonary arteries and arterioles which are constricted in late stages of COBD leading to ventilation/perfusion mismatching and further aggravating COPD. it will also help in delivering better antibiotic concentrations to the alveoli which help in better control of infection.

Interventions

DRUGInhaled nitroglycerin

Inhaled nitroglycerin

Sponsors

Beni-Suef University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient's ≥ 18 years old COPD exacerbation with respiratory failure and Echo evidenced presence of pulmonary hypertension (defined as mean pulmonary artery pressure \> 20 mmHg)

Exclusion criteria

* Profound left ventricular failure, as the decrease in pulmonary vascular resistance results in an increase in left ventricular preload. This may worsen cardiogenic pulmonary edema. * Pregnant female patients * Patient with hypersensitivity to nitroglycerin

Design outcomes

Primary

MeasureTime frameDescription
Change in pulmonary functions5 days after start of nebulized nitroglycerinChange in pulmonary functions Defined as: * Reduction of PaCO2 in arterial blood gases from admission value. * increase in Pao2 from admission value.

Secondary

MeasureTime frame
Number of days on mechanical ventilation5 days after start of nebulized nitroglycerin
Dose of vasopressor therapy5 days after start of nebulized nitroglycerin
Reduction of WBC count10 days after start of nebulized nitroglycerin
Mortality rate10 days after start of nebulized nitroglycerin

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026